| K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions JM Ostrem, U Peters, ML Sos, JA Wells, KM Shokat Nature 503 (7477), 548-551, 2013 | 2473 | 2013 |
| Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design JML Ostrem, KM Shokat Nature reviews Drug discovery 15 (11), 771-785, 2016 | 630 | 2016 |
| OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin L Chen, Y Shu, X Liang, EC Chen, SW Yee, AA Zur, S Li, L Xu, ... Proceedings of the National Academy of Sciences 111 (27), 9983-9988, 2014 | 243 | 2014 |
| A Ras-like domain in the light intermediate chain bridges the dynein motor to a cargo-binding region CM Schroeder, JML Ostrem, NT Hertz, RD Vale Elife 3, e03351, 2014 | 96 | 2014 |
| Compositions and methods for treating cancer J Ostrem, U Peters, KM Shokat US Patent App. 14/391,369, 2015 | 58 | 2015 |
| Compositions and methods for treating cancer J Ostrem, U Peters, KM Shokat US Patent 10,023,588, 2018 | 48 | 2018 |
| Overcoming KRAS-Mutant Lung Cancer J Luo, J Ostrem, B Pellini, D Imbody, Y Stern, HS Solanki, EB Haura, ... American Society of Clinical Oncology Educational Book 41, 700-710, 2022 | 31 | 2022 |
| Rational screening for cooperativity in small-molecule inducers of protein–protein associations S Liu, B Tong, JW Mason, JM Ostrem, A Tutter, BK Hua, SA Tang, ... Journal of the American Chemical Society 145 (42), 23281-23291, 2023 | 27 | 2023 |
| Targeting KRAS G12C with covalent inhibitors JML Ostrem, KM Shokat Annual Review of Cancer Biology 6 (1), 49-64, 2022 | 25 | 2022 |
| Compositions and methods for treating cancer J Ostrem, U Peters, KM Shokat US Patent 11,008,334, 2021 | 10 | 2021 |
| Compositions and methods for treating cancer J Ostrem, U Peters, KM Shokat US Patent 11,603,376, 2023 | 7 | 2023 |
| Compositions and methods for treating cancer J Ostrem, U Peters, KM Shokat US Patent App. 16/013,271, 2019 | 5 | 2019 |
| Direct RAS inhibitors turn 10 JML Ostrem, U Peters, KM Shokat Nature chemical biology 20 (10), 1238-1241, 2024 | 3 | 2024 |
| Compositions and methods for treating cancer J Ostrem, U Peters, KM Shokat US Patent 11,718,630, 2023 | 1 | 2023 |
| Compositions and methods for treating cancer J Ostrem, U Peters, KM Shokat US Patent App. 18/490,700, 2024 | | 2024 |
| Compositions and methods for treating cancer J Ostrem, U Peters, KM Shokat US Patent 11,891,402, 2024 | | 2024 |
| Highly specific intracellular ubiquitination of a small molecule W Li, EM Garcia-Rivera, DC Mitchell, JM Chick, M Maetani, JM Knapp, ... bioRxiv, 2024 | | 2024 |
| Small molecule activation of the tumor suppressor kinase LKB1 LS Kretschmer, DC Mitchell, J Liu, LA Wang, Z Wang, C He, L Ding, ... bioRxiv, 2024.12. 17.628051, 2024 | | 2024 |
| Associations of frailty with overall survival (OS) and functional decline among older adults with non–small-cell lung cancer (NSCLC) receiving chemotherapy, immunotherapy, and … HJ Lee, LC Walter, AK Smith, Y Shi, WJ Boscardin, HJ Cohen, ... Journal of Clinical Oncology 41 (16_suppl), 12040-12040, 2023 | | 2023 |
| Abstract PL04-03: Selective inhibition of K-Ras G12C through allosteric control of GTP affinity and effector interactions. JM Ostrem, U Peters, ML Sos, JA Wells, KM Shokat Molecular Cancer Therapeutics 12 (11_Supplement), PL04-03-PL04-03, 2013 | | 2013 |